Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesus Corria-Osorio

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2024
Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma ModelChakradhar Yakkala, Jesus Corria-Osorio, Lana Kandalaft, et al.
Nature Communications|May 21, 2021
Interpretation of T cell states from single-cell transcriptomics data using reference atlasesMassimo Andreatta, Jesus Corria-Osorio, Sören Müller, et al.
Ebiomedicine|September 5, 2019
Modulation of CD4 T cell function via CD6-targetingRaquel Filipa Freitas, Afonso Basto, Silvia C P Almeida, et al.
Nature Biotechnology|March 5, 2020
Author Correction: A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapyGreta Giordano-Attianese, Pablo Gainza, Elise Gray-Gaillard, et al.
Nature Biotechnology|February 5, 2020
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapyGreta Giordano-Attianese, Pablo Gainza, Elise Gray-Gaillard, et al.
Nature Immunology|April 20, 2023
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8<sup>+</sup> T cellsJesus Corria-Osorio, Santiago J Carmona, Evangelos Stefanidis, et al.
Immunity|September 14, 2024
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanomaJohanna Chiffelle, David Barras, Rémy Pétremand, et al.
Cancer Discovery|September 4, 2021
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to ImmunotherapyFernanda G Herrera, Catherine Ronet, Maria Ochoa de Olza, et al.
Nature|April 24, 2024
PGE<sub>2</sub> inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial functionMatteo Morotti, Alizee J Grimm, Helen Carrasco Hope, et al.
Science Immunology|February 2, 2024
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8<sup>+</sup> T-myeloid cell networks in melanomaDavid Barras, Eleonora Ghisoni, Johanna Chiffelle, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2024
Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma ModelChakradhar Yakkala, Jesus Corria-Osorio, Lana Kandalaft, et al.
Nature Communications|May 21, 2021
Interpretation of T cell states from single-cell transcriptomics data using reference atlasesMassimo Andreatta, Jesus Corria-Osorio, Sören Müller, et al.
Ebiomedicine|September 5, 2019
Modulation of CD4 T cell function via CD6-targetingRaquel Filipa Freitas, Afonso Basto, Silvia C P Almeida, et al.
Nature Biotechnology|March 5, 2020
Author Correction: A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapyGreta Giordano-Attianese, Pablo Gainza, Elise Gray-Gaillard, et al.
Nature Biotechnology|February 5, 2020
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapyGreta Giordano-Attianese, Pablo Gainza, Elise Gray-Gaillard, et al.
Nature Immunology|April 20, 2023
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8<sup>+</sup> T cellsJesus Corria-Osorio, Santiago J Carmona, Evangelos Stefanidis, et al.
Immunity|September 14, 2024
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanomaJohanna Chiffelle, David Barras, Rémy Pétremand, et al.
Cancer Discovery|September 4, 2021
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to ImmunotherapyFernanda G Herrera, Catherine Ronet, Maria Ochoa de Olza, et al.
Nature|April 24, 2024
PGE<sub>2</sub> inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial functionMatteo Morotti, Alizee J Grimm, Helen Carrasco Hope, et al.
Science Immunology|February 2, 2024
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8<sup>+</sup> T-myeloid cell networks in melanomaDavid Barras, Eleonora Ghisoni, Johanna Chiffelle, et al.
Pageof 1